Panbela Therapeutics Inc. PBLA
0.01
0.00
0.00%
as of 24 Sep
- Market cap
- $3.4M
- P/E
- 0.0×
Follow PBLA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.16 | 0.18 | 1.13 | 1.76 | 7.15 | 4.62 | 0.23 | 0.25 |
Net Debt/EBITDA |
(0.55) | (0.28) | 0.00 | 1.04 | 1.57 | 1.19 | (0.14) | (0.10) |
Debt/Assets |
373.66% | 0.00% | 18.44% | 3.69% | 0.00% | 0.00% | 124.43% | 44.01% |
Debt/Equity |
(0.71) | (0.49) | 1.31 | 0.08 | 0.00 | 0.00 | (0.77) | (1.10) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.47 | 0.33 | 0.40 | 0.44 | 0.81 | 0.71 | 0.44 | 1.00 |
Capex/Depreciation |
— | — | — | 0.00 | — | — | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 122.72% | 249.05% | 345.22% | (750.15%) | (96.98%) | (108.63%) | (3,230.05%) | 396.00% | |
| (621.90%) | (2,365.79%) | (622.23%) | (245.93%) | (73.60%) | (89.35%) | (391.41%) | (301.11%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
110.12% | 304.85% | (2,721.20%) | (464.77%) | (56.82%) | (105.36%) | 576.83% | 272.88% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.77) | (38.14) | (612.05) | (13,695.00) | (12,846.67) | (14,490.00) | (19,920.00) | (227.97) |
Cash per Share |
0.14 | 1.70 | 360.26 | 12,245.00 | 30,073.33 | 23,734.00 | 1,606.25 | 23.65 |
Shareholders Equity per Share |
(1.49) | (41.36) | 68.72 | 6,925.00 | 28,160.00 | 20,424.00 | (10,061.25) | (43.21) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Book value per Share |
(1.49) | (41.36) | 68.72 | 6,925.00 | 28,160.00 | 20,424.00 | (10,061.25) | (43.21) |
Free Cash Flow |
(2.40) | (3.40) | (2.39) | (2.74) | (3.85) | (7.24) | (15.94) | (24.85) |
Working Capital |
(4.64) | (3.40) | 0.22 | 1.33 | 8.39 | 9.62 | (6.06) | (9.26) |
Capital Expenditures |
— | — | — | — | — | — | (0.66) | 0.40 |
Net Current Asset Value |
(4.64) | (3.69) | 0.22 | 1.33 | 8.39 | 9.62 | (11.25) | (13.45) |
| Other line items | ||||||||
Quick Ratio |
0.14 | 0.14 | 1.07 | 1.60 | 6.85 | 4.58 | 0.17 | 0.22 |
Depreciation/Fixed assets |
— | — | — | 0.00 | — | — | — | — |
Cash ROIC |
258.68% | 198.71% | (117.99%) | (69.34%) | (22.06%) | (32.81%) | 2,680.00% | (824.59%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.77) | (38.14) | (612.05) | (13,695.00) | (12,846.67) | (14,490.00) | (19,095.00) | (231.64) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (825.00) | 3.67 |
Average Receivables |
0.37 | 0.37 | 0.38 | 0.35 | 0.34 | 0.32 | 0.19 | 0.12 |
Average Payables |
— | 1.13 | 1.13 | 0.83 | 0.58 | 0.60 | 1.75 | 6.40 |
Average Assets |
0.82 | 0.44 | 0.95 | 2.52 | 6.48 | 11.34 | 8.93 | 8.39 |
Average Common Equity |
(4.17) | (4.17) | (1.71) | 0.83 | 4.92 | 9.33 | 1.08 | (6.38) |
Capex to Sales |
— | — | — | — | — | — | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates